Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Shorts have to cover. There is no way around it :
X 1. Cash Flow Positive Status - 4 years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. In house marketing and distribution: Kirkov
__6. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
__7. Prevail over Purdue in Generic OxyContin infringement suit
X 8. DEA increases manufacturing quotas of Adderall & Vyvance
X 9. Double digit quarterly revenues in millions.
__10. Full ownership of Adderall IR $ 335 Million
__11. Full ownership of Adderall XR $ 1.56 Billion
__12. Generic Concerta- $1.2 BILLION submission
X 13. Generic Vyvanse- $5.1 BILLION - submitted to FDA Dec 2023
__14. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__15. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__16. Patented Unique ADF (w/o naltrexone)-- NDA
__17. Mikah ANDA (s)
__18. Undisclosed ANDAs/NDAs
__19. Antimetabolite ANDA- Methotrexate -$600 Million
__20. Undisclosed Antimetabolite ANDA- $42 Million
X 21. Prasco/Burel Adderall agreement January 1st 2024
X 22. First shipment Adderal XR to PRASCO Dec 2023
__23. Generic Vyvanse Approval
__24. Triple digit yearly revenues in millions.
__25. European distribution Dexcel partnership approval by Israeli Health
__26. Purchase or rent additional manufacturing and storage space for new ANDAs
__27. DollarLand PPS
__28. Uplist to the NASDAQ Exchange
__29. THE Buy Out !
__30. Vegas Baby !!!!!!!